1. Home
  2. ACAD vs AVAL Comparison

ACAD vs AVAL Comparison

Compare ACAD & AVAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACAD
  • AVAL
  • Stock Information
  • Founded
  • ACAD 1993
  • AVAL 1994
  • Country
  • ACAD United States
  • AVAL Colombia
  • Employees
  • ACAD N/A
  • AVAL N/A
  • Industry
  • ACAD Biotechnology: Pharmaceutical Preparations
  • AVAL Commercial Banks
  • Sector
  • ACAD Health Care
  • AVAL Finance
  • Exchange
  • ACAD Nasdaq
  • AVAL Nasdaq
  • Market Cap
  • ACAD 2.8B
  • AVAL 2.4B
  • IPO Year
  • ACAD 2004
  • AVAL N/A
  • Fundamental
  • Price
  • ACAD $16.61
  • AVAL $2.75
  • Analyst Decision
  • ACAD Buy
  • AVAL
  • Analyst Count
  • ACAD 17
  • AVAL 0
  • Target Price
  • ACAD $24.00
  • AVAL N/A
  • AVG Volume (30 Days)
  • ACAD 1.5M
  • AVAL 121.0K
  • Earning Date
  • ACAD 05-07-2025
  • AVAL 05-15-2025
  • Dividend Yield
  • ACAD N/A
  • AVAL 4.46%
  • EPS Growth
  • ACAD N/A
  • AVAL 37.36
  • EPS
  • ACAD 1.36
  • AVAL 0.01
  • Revenue
  • ACAD $957,797,000.00
  • AVAL $2,661,902,702.00
  • Revenue This Year
  • ACAD $13.07
  • AVAL $58.33
  • Revenue Next Year
  • ACAD $9.97
  • AVAL $9.86
  • P/E Ratio
  • ACAD $12.28
  • AVAL $13.71
  • Revenue Growth
  • ACAD 31.85
  • AVAL 0.20
  • 52 Week Low
  • ACAD $14.15
  • AVAL $1.94
  • 52 Week High
  • ACAD $20.68
  • AVAL $3.32
  • Technical
  • Relative Strength Index (RSI)
  • ACAD 36.91
  • AVAL 45.15
  • Support Level
  • ACAD $16.86
  • AVAL $2.70
  • Resistance Level
  • ACAD $17.31
  • AVAL $2.82
  • Average True Range (ATR)
  • ACAD 0.51
  • AVAL 0.11
  • MACD
  • ACAD -0.00
  • AVAL -0.03
  • Stochastic Oscillator
  • ACAD 23.24
  • AVAL 32.13

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

About AVAL Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

Grupo Aval Acciones y Valores SA is a Colombian financial services company. Its local operations consist of commercial banking (Banco de Bogota, Banco de Occidente, Banco Popular, and Banco AV Villas), pension fund management (Porvenir), and merchant banking (Corficolombiana). Outside Colombia, the company offers (via BAC Credomatic operations) consumer and credit card banking businesses in Central American countries (Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama) and Mexico. BAC Credomatic has key alliances with major credit card networks, such as Visa, MasterCard, American Express, and Diners Club.

Share on Social Networks: